Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Purpose: Osteosarcoma (OS) is the most common primary bone tumor. Despite complete surgical removal and intensive chemotherapeutic treatment, 30%-35% of patients with OS have local or systemic recurrence. Some patients survive multiple recurrences, but overall survival after OS recurrence is poor. This analysis aims to describe and identify factors influencing post-relapse survival (PRS) after a second OS relapse. Methods: This is a retrospective analysis of 60 patients with a second relapse of OS of the extremities in 2 Italian centers between 2003 and 2013. Results: Treatment for first and subsequent relapses was planned according to institutional guidelines. After complete surgical remission (CSR) following the first recurrence, patients experienced a second OS relapse with a median disease-free interval (DFI) of 6 months. Lung disease was prevalent: 44 patients (76%) had pulmonary metastases. Survival after the second relapse was 22% at 5 years. Lung disease only correlated with better survival at 5 years (33.6%) compared with other sites of recurrence (5%; p = 0.008). Patients with a single pulmonary lesion had a better 5-year second PRS (42%; p = 0.02). Patients who achieved a second CSR had a 5-year second PRS of 33.4%. Chemotherapy (p<0.001) benefited patients without a third CSR. Conclusions: This analysis confirms the importance of an aggressive, repeated surgical approach. Lung metastases only, the number of lesions, DFI and CSR influenced survival. It also confirms the importance of chemotherapy in patients in whom surgical treatment is not feasible.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prognosis for patients with recurrent osteosarcoma is poor [1–4].”
From Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial (2021) · cites this paper as [4]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 18 · Cited by 31
Research works printed but not linked: 3
- Raymond AK, 2002, World Health Organization Classification of Tumours. Tumours of soft tissue and bone, 264
- ESMO/European Sarcoma Network Working Group, 2014, Ann Oncol, 25
- Paioli A, Book of Abstracts, 27th Annual Meeting of the European Musculo-Skeletal Oncology Society (EMSOS)
Metadata
- Authors
- Tirtei, E., Asaftei, S. D., Manicone, R., Cesari, M., Paioli, A., Rocca, M., Ferrari, S., & Fagioli, F.
- Affiliations
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Istituto Ortopedico Rizzoli (IT)
- Corresponding author
- Tirtei, Elisa
- ORCID
- Venue
- Tumori Journal
- Publisher
- SAGE Publications
- Published
- 2018-06
- Volume
- 104
- Issue
- 3
- Pages
- 202-206
- ISSN
- 0300-8916 (ISSN-L)
- 2038-2529
- OpenAlex
- W4256385699
- Cited by
- 31
- References
- 18
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 3
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Tumori Journal (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- osteosarcoma, second relapse, survival after relapse, lung metastasis, disease-free interval, chemotherapy, limb-sparing surgery, prognostic factors, extremity osteosarcoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. https://app.cochat.ai/papers/10.1177/0300891617753257
- The paper
- Tirtei, E., Asaftei, S. D., Manicone, R., Cesari, M., Paioli, A., Rocca, M., Ferrari, S., & Fagioli, F. (2018). Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori Journal. https://doi.org/10.1177/0300891617753257
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.